194 related articles for article (PubMed ID: 36600534)
1. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
RAINBO Research Consortium
Int J Gynecol Cancer; 2022 Dec; 33(1):109-17. PubMed ID: 36600534
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer.
Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S
Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529
[TBL] [Abstract][Full Text] [Related]
3. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
4. PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.
Loukovaara M; Bützow R; Staff S; Mäenpää M; Faltinová M; Lassus H; Veijalainen O; Grönvall M; Vaalavirta L; Kuikka E; Haataja M; Urpilainen E; Simojoki M; Anttila M; Auranen A
Int J Gynecol Cancer; 2023 Nov; 33(11):1807-1811. PubMed ID: 37813479
[TBL] [Abstract][Full Text] [Related]
5. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
[TBL] [Abstract][Full Text] [Related]
6. A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020.
Obermair A; Nicklin J; Gebski V; Hayes SC; Graves N; Mileshkin L; Lin MY; Beale P; Baxter E; Robledo K; Salomon C; Hanna GB; Janda M
Int J Gynecol Cancer; 2021 Dec; 31(12):1595-1601. PubMed ID: 34728527
[TBL] [Abstract][Full Text] [Related]
7. Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).
Li Y; Zhu C; Xie H; Chen Y; Lv W; Xie X; Wang X
J Gynecol Oncol; 2023 Mar; 34(2):e37. PubMed ID: 36659832
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial).
Grassi T; Mariani A; Cibula D; Soliman PT; Suman VJ; Weaver AL; Pedra Nobre S; Weigelt B; Glaser GE; Cappuccio S; Abu-Rustum NR
Int J Gynecol Cancer; 2020 Oct; 30(10):1627-1632. PubMed ID: 32699021
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
11. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
Horeweg N; Nout RA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Haverkort MAD; Mens JWM; Slot A; Wortman BG; de Boer SM; Stelloo E; Verhoeven-Adema KW; Putter H; Smit VTHBM; Bosse T; Creutzberg CL;
J Clin Oncol; 2023 Sep; 41(27):4369-4380. PubMed ID: 37487144
[TBL] [Abstract][Full Text] [Related]
12. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
[TBL] [Abstract][Full Text] [Related]
14. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
J Gynecol Oncol; 2023 Sep; 34(5):e85. PubMed ID: 37593813
[TBL] [Abstract][Full Text] [Related]
15. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
Int J Gynaecol Obstet; 2023 Aug; 162(2):383-394. PubMed ID: 37337978
[TBL] [Abstract][Full Text] [Related]
16. [Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer].
Espenel S; Pointreau Y; Genestie C; Durdux C; Haie-Meder C; Chargari C
Cancer Radiother; 2022 Oct; 26(6-7):931-937. PubMed ID: 36031498
[TBL] [Abstract][Full Text] [Related]
17. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
[TBL] [Abstract][Full Text] [Related]
18. A multicenter noninferior randomized controlled study of sentinel lymph node biopsy alone versus sentinel lymph node biopsy plus lymphadenectomy for patients with stage I endometrial cancer, INSEC trial concept.
Guo Y; Sun L; Chen X; Wen Q; Shao Z; Tang X; Shi X; Wang J; Zhang Y; Zhu T
BMC Cancer; 2023 Dec; 23(1):1184. PubMed ID: 38041023
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy for advanced endometrial cancer.
Galaal K; Al Moundhri M; Bryant A; Lopes AD; Lawrie TA
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010681. PubMed ID: 24832785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]